{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T23:17:56Z","timestamp":1769642276602,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite recent advances in the treatment of acute heart failure (AHF), implementation of new evidence into clinical practice remains challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a\u00a0single-center descriptive exploratory study within an ongoing prospective AHF registry. Adult patients admitted with AHF, without requiring intensive care, were included consecutively. An updated local AHF protocol was developed and implemented by group-education sessions, pocket cards, and posters. Patients before (control group) and after (intervention group) implementation of the new protocol were compared in terms of compliance to the protocol and 90-day outcomes\u2014blanking the implementation period. Subgroups entailed HF with (mildly) reduced and preserved ejection fraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients were elderly, with almost half being de novo HF patients. Groups were comparable except for higher NT-proBNP in the implementation group and a\u00a0higher cancer prevalence in the control group. The intervention group showed an increase in in-hospital use of acetazolamide (59.8 vs 0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090.001), in iron deficiency testing and correct iv. iron administration (42.9% vs 78.6%\n                      <jats:italic>p<\/jats:italic>\n                      \u202f\u2264\u20090.001). Pre-discharge installation of SGLT2 inhibitors showed a\u00a0positive trend (44.2 vs 20% in HF(m)rEF patients and 29.4 vs 4% in HFpEF, both\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.01) HF-event-free survival at 90\u00a0days numerically favored the intervention group (29.9 vs 44.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.054), whereas length of hospital stay increased by 1\u00a0day (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.011).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Implementing a\u00a0local updated AHF protocol improved adoption of several evidence based AHF interventions. This may translate into improved patient outcomes, against a\u00a0minor increase in hospital duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12471-025-02004-8","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T01:02:00Z","timestamp":1767574920000},"page":"46-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PRACTICE-HF: Implementation of an updated clinical protocol for acute heart failure"],"prefix":"10.1007","volume":"34","author":[{"given":"Lukas","family":"Peeters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mick","family":"Hoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delian","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjorn","family":"Hompes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Langenveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danae","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Lenderink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Peter","family":"Brunner-La Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Sanders-van Wijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"1","key":"2004_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.34172\/jcvtr.2022.08","volume":"14","author":"N Naderi","year":"2022","unstructured":"Naderi\u00a0N, Chenaghlou\u00a0M, Mirtajaddini\u00a0M, et\u00a0al. Predictors of readmission in hospitalized heart failure patients. J\u00a0Cardiovasc Thorac Res. 2022;14(1):11\u20137.","journal-title":"J Cardiovasc Thorac Res"},{"issue":"10367","key":"2004_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa\u00a0A, Davison\u00a0B, Chioncel\u00a0O, et\u00a0al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a\u00a0multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938\u201352.","journal-title":"Lancet"},{"issue":"36","key":"2004_CR3","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M, et\u00a0al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"10","key":"2004_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ejhf.1531","volume":"21","author":"PM Seferovic","year":"2019","unstructured":"Seferovic\u00a0PM, Ponikowski\u00a0P, Anker\u00a0SD, et\u00a0al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(10):1169\u201386.","journal-title":"Eur J Heart Fail"},{"issue":"10266","key":"2004_CR5","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski\u00a0P, Kirwan\u00a0B, Anker\u00a0SD, et\u00a0al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a\u00a0multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396(10266):1895\u2013904.","journal-title":"Lancet"},{"issue":"1","key":"2004_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/ehf2.14604","volume":"11","author":"PRD Clephas","year":"2024","unstructured":"Clephas\u00a0PRD, Malgie\u00a0J, Schaap\u00a0J, et\u00a0al. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE-HF. Esc Heart Fail. 2024;11(1):550\u20139.","journal-title":"Esc Heart Fail"},{"issue":"1","key":"2004_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","volume":"44","author":"J Biegus","year":"2023","unstructured":"Biegus\u00a0J, Voors\u00a0AA, Collins\u00a0SP, et\u00a0al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart\u00a0J. 2023;44(1):41\u201350.","journal-title":"Eur Heart J"},{"issue":"2","key":"2004_CR8","doi-asserted-by":"publisher","first-page":"e007034","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034","volume":"14","author":"DD Berg","year":"2021","unstructured":"Berg\u00a0DD, Samsky\u00a0MD, Velazquez\u00a0EJ, et\u00a0al. Efficacy and safety of sacubitril\/valsartan in high-risk patients in the PIONEER-HF trial. Circ Heart Fail. 2021;14(2):e7034.","journal-title":"Circ Heart Fail"},{"issue":"37","key":"2004_CR9","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M, et\u00a0al. Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"key":"2004_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","volume":"7(1","author":"H Brunner-La Rocca","year":"2019","unstructured":"Brunner-La Rocca\u00a0H, Linssen\u00a0GC, Smeele\u00a0FJ, et\u00a0al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF Registry. JACC Heart Fail. 2019;7(1:13\u201321.","journal-title":"JACC Heart Fail"},{"issue":"13","key":"2004_CR11","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"Mullens\u00a0W, Dauw\u00a0J, Martens\u00a0P, et\u00a0al. Acetazolamide in acute decompensated heart failure with volume overload. N\u00a0Engl J Med. 2022;387(13):1185\u201395.","journal-title":"N Engl J Med"},{"issue":"12","key":"2004_CR12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Claggett\u00a0B, et\u00a0al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N\u00a0Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"key":"2004_CR13","unstructured":"Zorginstituut Nederland. Verslag van de vergadering van de Wetenschappelijke Adviesraad (WAR) over sacubitril\/valsartan (Entresto\u00ae). Zorginstituut Nederland. 2022;14\/11."},{"issue":"2","key":"2004_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ejhf.3081","volume":"26","author":"D Tomasoni","year":"2024","unstructured":"Tomasoni\u00a0D, Pagnesi\u00a0M, Colombo\u00a0G, et\u00a0al. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: an analysis from the HELP-HF registry. Eur J Heart Fail. 2024;26(2):327\u201337.","journal-title":"Eur J Heart Fail"},{"key":"2004_CR15","unstructured":"Sauer AJ, Beon C, Cherkur S, et\u00a0al. Multiregional implementation initiative\u2019s impact on guideline-based performance measures for patients hospitalized with heart failure: IMPLEMENT-HF. Circ Heart Fail.0(0):e12547\u20130."},{"key":"2004_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijcard.2018.01.067","volume":"258","author":"J Rubio-Gracia","year":"2018","unstructured":"Rubio-Gracia\u00a0J, Demissei\u00a0BG, Ter Maaten\u00a0JM, et\u00a0al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018;258:185\u201391.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2004_CR17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/ehf2.13737","volume":"9","author":"DH van Dalen","year":"2022","unstructured":"van Dalen\u00a0DH, Kragten\u00a0JA, Emans\u00a0ME, et\u00a0al. Acute heart failure and iron deficiency: a\u00a0prospective, multicentre, observational study. Esc Heart Fail. 2022;9(1):398\u2013407.","journal-title":"Esc Heart Fail"},{"issue":"11","key":"2004_CR18","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ejhf.765","volume":"19","author":"HGC Van Spall","year":"2017","unstructured":"Van Spall\u00a0HGC, Rahman\u00a0T, Mytton\u00a0O, et\u00a0al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a\u00a0systematic review and network meta-analysis. Eur J Heart Fail. 2017;19(11):1427\u201343.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2004_CR19","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/S2214-109X(20)30004-8","volume":"8","author":"J Tromp","year":"2020","unstructured":"Tromp\u00a0J, Bamadhaj\u00a0S, Cleland\u00a0JGF, et\u00a0al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a\u00a0cohort study. Lancet Glob Health. 2020;8(3):e411\u201320.","journal-title":"Lancet Glob Health"},{"issue":"10","key":"2004_CR20","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","volume":"29","author":"JM Ter Maaten","year":"2023","unstructured":"Ter Maaten\u00a0JM, Beldhuis\u00a0IE, Van Der Meer\u00a0P, et\u00a0al. Natriuresis-guided diuretic therapy in acute heart failure: a\u00a0pragmatic randomized trial. Nat Med. 2023;29(10):2625.","journal-title":"Nat Med"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-02004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-025-02004-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-02004-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:39:50Z","timestamp":1769596790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-025-02004-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2004"],"URL":"https:\/\/doi.org\/10.1007\/s12471-025-02004-8","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.P.\u00a0Brunner-La Rocca received speaker\/consulting fees from Novartis, AstraZeneca, Boehringer Ingelheim, Roche diagnostics and Novo Nordisk and unrestricted research grants from Novartis and Roche diagnostics. S.\u00a0Sanders-van Wijk received speaker\/consulting fees from Novartis, Bayer, Astra Zeneca, Boehringer Ingelheim, Pfizer, Roche diagnostics and Novo Nordisk and grant support from Astra Zeneca and the CRL fund (Cardiologie research Limburg). L.\u00a0Peeters, M.\u00a0Hoen, D.\u00a0Hofman, B.\u00a0Hompes, B.\u00a0Langenveld, D.\u00a0Smeets and T.\u00a0Lenderink declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}